PE20160523A1 - Derivados de arilo o heteroarilo como inhibidores de moleculas pequenas de fibrosis - Google Patents
Derivados de arilo o heteroarilo como inhibidores de moleculas pequenas de fibrosisInfo
- Publication number
- PE20160523A1 PE20160523A1 PE2015002576A PE2015002576A PE20160523A1 PE 20160523 A1 PE20160523 A1 PE 20160523A1 PE 2015002576 A PE2015002576 A PE 2015002576A PE 2015002576 A PE2015002576 A PE 2015002576A PE 20160523 A1 PE20160523 A1 PE 20160523A1
- Authority
- PE
- Peru
- Prior art keywords
- heteroaryl
- aryl
- fibrosis
- inhibitors
- derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
Se describen aqui compuestos y composiciones para el tratamiento de una enfermedad fibrotica en donde A1 y A2 son arilo o heteroarilo; B es formula I, C es heterociclilo de 5 o 6 miembros opcionalmente sustituido o heteroarilo de 5 o 6 miembros opcionalmente sustituido, en donde el heterociclilo o el heteroarilo contiene 1 a 4 atomos de nitrogeno; D es arilo o heteroarilo; E es arilo o heteroarilo, carbociclilo, o el heterociclilo, o alquilo; cada R1, R2, R3, y R4 es H, alquilo, etc. X1 y X2 son N o CR5; R5 es H, OH, alquilo, o alcoxi; cada R6 es alquilo, haloalquilo, etc.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361832768P | 2013-06-07 | 2013-06-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20160523A1 true PE20160523A1 (es) | 2016-05-25 |
Family
ID=52008597
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2015002576A PE20160523A1 (es) | 2013-06-07 | 2014-06-05 | Derivados de arilo o heteroarilo como inhibidores de moleculas pequenas de fibrosis |
Country Status (20)
Country | Link |
---|---|
US (2) | US9663499B2 (es) |
EP (2) | EP3626242A1 (es) |
JP (1) | JP6414831B2 (es) |
KR (1) | KR102240329B1 (es) |
CN (1) | CN105392364B (es) |
AU (1) | AU2014274830B2 (es) |
BR (1) | BR112015030203A2 (es) |
CA (1) | CA2913634C (es) |
CL (1) | CL2015003569A1 (es) |
DK (1) | DK3003038T3 (es) |
EA (1) | EA201592157A1 (es) |
ES (1) | ES2755125T3 (es) |
HK (1) | HK1221606A1 (es) |
MX (1) | MX2015016783A (es) |
PE (1) | PE20160523A1 (es) |
PL (1) | PL3003038T3 (es) |
PT (1) | PT3003038T (es) |
SG (1) | SG11201510011VA (es) |
TN (1) | TN2015000519A1 (es) |
WO (1) | WO2014197738A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY198422A (en) | 2009-04-29 | 2023-08-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
KR20120016677A (ko) | 2009-06-15 | 2012-02-24 | 아마린 파마, 인크. | 병용 스타틴 요법을 받는 대상체에서 ldl-c 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법 |
NZ611606A (en) | 2010-11-29 | 2015-10-30 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US9192609B2 (en) | 2013-04-17 | 2015-11-24 | Hedgepath Pharmaceuticals, Inc. | Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors |
EP3626242A1 (en) | 2013-06-07 | 2020-03-25 | The Scripps Research Institute | Itraconazole analogs as inhibitors of fibrosis |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
WO2016094570A1 (en) * | 2014-12-10 | 2016-06-16 | The California Institute For Biomedical Research | Small molecule inhibitors of fibrosis |
IL243707A0 (en) | 2016-01-20 | 2016-05-01 | Galmed Res And Dev Ltd | Treatment to regulate the microbiota in the intestine |
EP3445385A4 (en) * | 2016-04-18 | 2019-11-20 | The Trustees of Columbia University in the City of New York | THERAPEUTIC GOALS INVOLVED IN THE PROGRESSION OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) |
US11197870B2 (en) | 2016-11-10 | 2021-12-14 | Galmed Research And Development Ltd | Treatment for hepatic fibrosis |
CN106866459A (zh) * | 2017-03-30 | 2017-06-20 | 成都绿林科技有限公司 | 一种抗真菌药物中间体的制备方法 |
CN106986787A (zh) * | 2017-03-30 | 2017-07-28 | 成都绿林科技有限公司 | 一种泊沙康唑中间体的合成方法 |
EP3768270A4 (en) * | 2018-03-19 | 2021-12-08 | Sheo Pharmaceuticals | METHODS AND COMPOSITIONS FOR TREATING IDIOPATHIC PULMONARY FIBROSIS |
JP7020756B2 (ja) | 2018-09-24 | 2022-02-16 | アマリン ファーマシューティカルズ アイルランド リミテッド | 対象の心血管イベントのリスクを低減する方法 |
EP3863723A4 (en) * | 2018-10-14 | 2022-09-07 | The University of Chicago | COMPOSITIONS AND METHODS FOR ACTIVATING NRF2-DEPENDENT GENE EXPRESSION |
US20210308089A1 (en) * | 2020-04-07 | 2021-10-07 | Amarin Pharmaceuticals Ireland Limited | Methods of treating and/or preventing viral infections and/or diseases caused by viruses in a subject in need thereof |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4267179A (en) | 1978-06-23 | 1981-05-12 | Janssen Pharmaceutica, N.V. | Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles |
US4619931A (en) * | 1983-02-28 | 1986-10-28 | Janssen Pharmaceutica, N.V. | [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles |
US4791111A (en) * | 1985-12-23 | 1988-12-13 | Janssen Pharmaceutica, N.V. | [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles having anti-microbial properties |
IL103558A0 (en) | 1991-10-30 | 1993-03-15 | Schering Corp | Tri-substituted tetrahydrofuran antifungals |
JPH09505106A (ja) | 1993-11-19 | 1997-05-20 | シエル・インターナシヨネイル・リサーチ・マーチヤツピイ・ベー・ウイ | ポリケトンポリマー組成物 |
US5521186A (en) | 1994-10-27 | 1996-05-28 | Janssen Pharmaceutica N.V. | Apolipoprotein-β synthesis inhibitors |
US5625064A (en) | 1995-04-19 | 1997-04-29 | Schering Corporation | Process for the preparation of triazolones |
TW457240B (en) | 1995-04-20 | 2001-10-01 | Janssen Pharmaceutica Nv | Novel triazolones as apolipoprotein-B synthesis inhibitors |
EP0957101A1 (en) | 1998-05-14 | 1999-11-17 | Janssen Pharmaceutica N.V. | Water soluble azoles as broad-spectrum antifungals |
US6498165B1 (en) | 1999-06-30 | 2002-12-24 | Merck & Co., Inc. | Src kinase inhibitor compounds |
EP1330448A2 (en) | 2000-06-20 | 2003-07-30 | Atherogenics, Inc. | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders |
EP1511490A4 (en) * | 2002-05-31 | 2009-03-11 | Transform Pharmaceuticals Inc | NOVEL CONAZOLE CRYSTALLINE FORMS AND RELATED METHODS, PHARMACEUTICAL COMPOSITIONS AND METHODS |
EA017918B1 (ru) | 2007-12-13 | 2013-04-30 | СИЕНА БИОТЕК С.п.А. | Антагонисты пути hedgehog и их терапевтические применения |
WO2010021681A2 (en) | 2008-08-18 | 2010-02-25 | Combinatorx (Singapore) Pte. Ltd. | Compositions and methods for treatment of viral diseases |
JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
US20110183948A1 (en) * | 2010-01-15 | 2011-07-28 | Infinity Pharmaceuticals, Inc. | Treatment of fibrotic conditions using hedgehog inhibitors |
GB201015079D0 (en) * | 2010-09-10 | 2010-10-27 | Helperby Therapeutics Ltd | Novel use |
WO2012047762A2 (en) | 2010-10-08 | 2012-04-12 | Amplyx Pharmaceuticals, Inc. | Antifungal agents |
JP6030567B2 (ja) | 2010-12-07 | 2016-11-24 | アミラ ファーマシューティカルス,インコーポレーテッド | 多環式lpa1アンタゴニストおよびその使用 |
WO2013036866A1 (en) * | 2011-09-07 | 2013-03-14 | The Johns Hopkins University | Itraconazole analogs and use thereof |
US10774132B2 (en) | 2012-01-09 | 2020-09-15 | The Scripps Research Instittue | Ultralong complementarity determining regions and uses thereof |
CN105849086B (zh) | 2012-11-24 | 2018-07-31 | 杭州多禧生物科技有限公司 | 亲水性链接体及其在药物分子和细胞结合分子共轭反应上的应用 |
LT3004106T (lt) | 2013-06-07 | 2018-02-26 | Rhizen Pharmaceuticals S.A. | Dvigubi selektyvūs p13 delta ir gamma kinazės inhibitoriai |
EP3626242A1 (en) | 2013-06-07 | 2020-03-25 | The Scripps Research Institute | Itraconazole analogs as inhibitors of fibrosis |
-
2014
- 2014-06-05 EP EP19191562.8A patent/EP3626242A1/en active Pending
- 2014-06-05 TN TN2015000519A patent/TN2015000519A1/en unknown
- 2014-06-05 PL PL14807059T patent/PL3003038T3/pl unknown
- 2014-06-05 BR BR112015030203A patent/BR112015030203A2/pt not_active IP Right Cessation
- 2014-06-05 MX MX2015016783A patent/MX2015016783A/es unknown
- 2014-06-05 AU AU2014274830A patent/AU2014274830B2/en active Active
- 2014-06-05 CN CN201480032411.7A patent/CN105392364B/zh active Active
- 2014-06-05 WO PCT/US2014/041174 patent/WO2014197738A1/en active Application Filing
- 2014-06-05 US US14/895,813 patent/US9663499B2/en active Active
- 2014-06-05 SG SG11201510011VA patent/SG11201510011VA/en unknown
- 2014-06-05 PE PE2015002576A patent/PE20160523A1/es not_active Application Discontinuation
- 2014-06-05 EA EA201592157A patent/EA201592157A1/ru unknown
- 2014-06-05 KR KR1020157036822A patent/KR102240329B1/ko active IP Right Grant
- 2014-06-05 JP JP2016518012A patent/JP6414831B2/ja active Active
- 2014-06-05 CA CA2913634A patent/CA2913634C/en active Active
- 2014-06-05 PT PT148070592T patent/PT3003038T/pt unknown
- 2014-06-05 EP EP14807059.2A patent/EP3003038B1/en active Active
- 2014-06-05 DK DK14807059T patent/DK3003038T3/da active
- 2014-06-05 ES ES14807059T patent/ES2755125T3/es active Active
-
2015
- 2015-12-07 CL CL2015003569A patent/CL2015003569A1/es unknown
-
2016
- 2016-08-20 HK HK16109962.7A patent/HK1221606A1/zh unknown
-
2017
- 2017-04-14 US US15/488,206 patent/US9981956B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN105392364A (zh) | 2016-03-09 |
PL3003038T3 (pl) | 2020-02-28 |
JP2016521710A (ja) | 2016-07-25 |
CA2913634C (en) | 2022-08-09 |
AU2014274830B2 (en) | 2017-11-09 |
MX2015016783A (es) | 2016-07-18 |
ES2755125T3 (es) | 2020-04-21 |
EP3003038B1 (en) | 2019-08-14 |
KR20160029028A (ko) | 2016-03-14 |
DK3003038T3 (da) | 2019-11-11 |
AU2014274830A1 (en) | 2015-11-26 |
JP6414831B2 (ja) | 2018-10-31 |
CA2913634A1 (en) | 2014-12-11 |
TN2015000519A1 (en) | 2017-04-06 |
EP3003038A4 (en) | 2016-11-16 |
PT3003038T (pt) | 2019-11-19 |
CL2015003569A1 (es) | 2016-11-11 |
BR112015030203A2 (pt) | 2017-07-25 |
US9981956B2 (en) | 2018-05-29 |
US20170217943A1 (en) | 2017-08-03 |
KR102240329B1 (ko) | 2021-04-14 |
EP3003038A1 (en) | 2016-04-13 |
SG11201510011VA (en) | 2016-01-28 |
CN105392364B (zh) | 2018-09-14 |
WO2014197738A1 (en) | 2014-12-11 |
US20160130258A1 (en) | 2016-05-12 |
US9663499B2 (en) | 2017-05-30 |
HK1221606A1 (zh) | 2017-06-09 |
EP3626242A1 (en) | 2020-03-25 |
EA201592157A1 (ru) | 2016-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20160523A1 (es) | Derivados de arilo o heteroarilo como inhibidores de moleculas pequenas de fibrosis | |
CO2018012171A2 (es) | Piridinas sustituidas con heteroarilo y métodos de uso | |
CY1124537T1 (el) | Παραγωγο πυριδονης που εχει τετραϋδροπυρανυλ μεθυλ ομαδα | |
CY1121549T1 (el) | Ενωσεις 1-αρυλκαρβονυλ-4-oξυ-πιπεριδινης χρησιμες για την αγωγη νευροεκφυλιστικων παθησεων | |
CY1121677T1 (el) | Ενωσεις διμεθυλοβενζοϊκου οξεος | |
CY1120188T1 (el) | ΠΑΡΑΓΩΓΑ ΝΑΦΘΥΡΙΔΙΝΗΣ ΧΡΗΣΙΜΑ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ ΙΝΤΕΓΚΡΙΝΗΣ αvβ6 | |
CY1121395T1 (el) | Τετραϋδροπυριδοπυραζινες-διαμορφωτες toy gpr6 | |
CY1119105T1 (el) | Παραγωγα διπυραζολιου ως αναστολεις jak | |
CY1121804T1 (el) | Καινοτομες ενωσεις πυριμιδινης και πυριδινης και η χρηση τους | |
CY1119583T1 (el) | Φαινοξυαιθυλο παραγωγα κυκλικης αμινης και η δραστικοτητα τους ως τροποποιητες του ερ4 υποδοχεα | |
UY34825A (es) | Síntesis de compuestos heterocíclicos | |
CY1119134T1 (el) | Υποδοχεις της νεπριλυσινης | |
EA201691085A1 (ru) | Замещенные бензамиды и способы их применения | |
CR20150470A (es) | Derivados de triazolona de piridinilo y piridinilo fusionado | |
CY1117688T1 (el) | Ενωσεις τετραϋδροπυρρολοθειαζινης | |
PH12014501719A1 (en) | Pyridone derivatives | |
PE20141558A1 (es) | Derivados de acido benzotiazol-6-il acetico y su uso para tratar una infeccion por vih | |
EA201690094A1 (ru) | Ингибиторы syk | |
CY1119220T1 (el) | Μονοκυκλικο παραγωγο πυριδινης | |
CR20130369A (es) | Novedosos derivados heterocíclicos | |
RS54730B1 (sr) | Inhibitori beta sekretaze | |
UA111626C2 (uk) | Похідні дигідрохінолін-2-ону | |
CO6821935A2 (es) | Derivados novedosos de cefalosporinas y cmposiciones farmacéuticas de estos | |
CY1121626T1 (el) | Νεο παραγωγο υδροξαμικου οξεος ή αλας αυτου | |
JO3318B1 (ar) | مثبطات bace |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |